This design enables the miniDC to exhibit DC-specific plasma membrane proteins such as MHC, CD86, and CD40, effectively mimicking natural DCs’ antigen-presenting functions while concurrently releasing IL-2 to activate T cells and trigger a strong antitumor immune response, presenting an enhanced method for immunotherapy against ovarian cancer [116]. This evidence concerns the gene IL2 and ovarian carcinoma.